Rusfertide Demonstrates Efficacy as a New Treatment for Polycythemia Vera

Rusfertide, a hepcidin mimetic, has shown promising results as a treatment for polycythemia vera, a rare blood disorder characterized by the overproduction of red blood cells. In the VERIFY clinical study, patients with polycythemia vera received either rusfertide in combination with the current standard of care or a placebo. The study found that the group receiving rusfertide met both the primary endpoint and key secondary endpoints, indicating a statistically significant improvement in clinical response rates compared to the placebo group. Additionally, patients treated with rusfertide experienced improvements in quality of life measures. These findings suggest that rusfertide could become a new therapeutic option for managing polycythemia vera, which is typically treated with phlebotomy and cytoreductive therapy. The results were published by Targeted Oncology.